Joller at EU health ministers’ meeting: new medicines must reach people faster and at a reasonable price

Imported from official source

Announcement

Safety Classified by Officially

Joller at EU health ministers’ meeting: new medicines must reach people faster and at a reasonable price

The central topic of the meeting was the European health biotechnology package, the aim of which is to support the development and uptake of novel biotechnological medicines, treatment methods and health technologies in Europe. New biotechnological solutions may mean better cancer treatment, more precise tests, faster diagnosis or new opportunities for treating diseases for which there is still no good treatment today.

According to Karmen Joller, biological medicines are one of the greatest breakthroughs in medicine in recent decades, with an impact comparable to that of antibiotics and vaccines. She emphasised that supporting innovation must be balanced with the availability of medicines. The European Union should not establish rules that unjustifiably delay the market entry of new and more affordable biosimilar medicines compared with the original. Biosimilars are often approximately 30 percent cheaper than original medicines.

“When one medicine has had a very high price for years and the emergence of competition is hindered, difficult choices have to be made - whose treatment can be funded immediately and whose treatment must wait. Our aim is for new medicines to reach people faster,” Joller said. “When fair competition emerges in the medicines market, patients win. The price falls, availability improves and the healthcare system can provide more help for the same money.”

From Estonia’s perspective, a longer protection period may be granted to new medicines only when there is a clear reason for it. For example, if the medicine helps with a disease for which there has so far been no good treatment, or gives the patient a clearly better outcome compared with existing medicines. If additional protection is granted too easily and competition is hindered, the market entry of cheaper medicines is delayed.

This is an extract. The publication continues at the source.

Source: Ministry of Social Affairs of Estonia.

Read the original at the source: https://sm.ee/en/news/joller-eu-health-ministers-meeting-new-medicines-must-reach-people-faster-and-reasonable-price

Officially imported this from Ministry of Social Affairs of Estonia’s own source and shows an extract. If you work there, claiming the profile and verifying the domain lets you choose to show the full text here.

Provenance

Organization
Ministry of Social Affairs of Estonia — imported from official source
Official source
https://www.sm.ee/en/rss-feeds/rss.xml RSS
Imported
October 03, 2026 20:32
Versions
1 recorded
Identity
4085 at https://www.sm.ee/en

Officially records where a publication came from, not whether it is true. Imported records are reproduced from an organization's own official source.